B&W Tek announces 1064nm portable Raman system
7 March 2013 | By B&W Tek
B&W Tek, Inc. is proud to announce the i-Raman® EX portable Raman spectrometer...
List view / Grid view
News
Roger M. Perlmutter appointed as President of Merck Research Laboratories
7 March 2013 | By Merck
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Roger M. Perlmutter, M.D., Ph.D., as executive vice president and president of Merck Research Laboratories (MRL), effective April 15. Dr. Perlmutter will succeed Peter S. Kim, Ph.D., who has served in the role…
ViiV Healthcare presents data from Phase III study of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1
6 March 2013 | By GlaxoSmithKline
24-week data from Phase III SAILING study...
FDA approves new Roche test to evaluate response to hepatitis C therapy
6 March 2013 | By Roche
Viral load test uses a novel dual-probe approach designed to manage patients being treated with antiviral therapies...
Gilead announces full 24-week Phase 2 results for once-daily single tablet HIV regimen containing novel prodrug TAF
5 March 2013 | By Gilead Sciences
TAF-based regimen now in Phase 3 development...
In Nigeria, a new project prompts easier insulin access
5 March 2013 | By Novo Nordisk
Novo Nordisk launches a new project to enhance the quality and accessibility of diabetes treatment in Nigeria...
Roche Chairman Franz B. Humer announces that he will not stand for re-election in 2014
5 March 2013 | By Roche
Roche to inform about plans for succession in autumn 2013...
Roche obtains EU approval for PERJETA
5 March 2013 | By Roche
Roche announced that the EMA has approved PERJETA (pertuzumab) for patients with previously untreated HER2-positive metastatic breast cancer (mBC)...
Pfizer presents Phase 3 safety and immunogenicity data on Prevnar 13® in adults with HIV
4 March 2013 | By Pfizer
Pfizer presented the results from a Phase 3 study...
Boehringer Ingelheim announces interim results from a Phase III trial in HIV patients co-infected with chronic hepatitis C
4 March 2013 | By Boehringer Ingelheim
Interim study results from STARTversoTM 4...
FDA accepts Biogen Idec’s Biologics License Application for first long-lasting factor IX therapy for hemophilia B
4 March 2013 | By Biogen Idec
“We are encouraged by the FDA’s acceptance of our application..."
Daiichi Sankyo announces organizational restructuring as of April 1, 2013
4 March 2013 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the following organizational changes taking place from April 1, 2013...
Baby born with AIDS virus appears to have been cured
3 March 2013 | By University of Mississippi
A baby born with the virus that causes AIDS appears to have been cured, scientists announced Sunday...
Sanofi and Regeneron report positive proof-of-concept data for Dupilumab
2 March 2013 | By Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting…
Novartis receives EU approval for Ilaris®
1 March 2013 | By Novartis
Novartis announced that the European Commission has approved llaris (canakinumab, ACZ885)...
